Have your own idea? Try our Stock Screener
Chinese (SSE) Pharma Industry Analysis
UpdatedSep 26, 2025
DataAggregated Company Financials
Companies217
- 7D-1.9%
- 3M15.9%
- 1Y37.7%
- YTD30.2%
Over the last 7 days, the Pharma industry has dropped 1.9%, driven by a pullback from BrightGene Bio-Medical Technology of 30%. On the other hand Shenzhen Salubris Pharmaceuticals is actually up 14%. Over the past 12 months, the industry was up 38%. As for the next few years, earnings are expected to grow by 21% per annum.
Industry Valuation and Performance
Has the Chinese Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 26 Sep 2025 | CN¥3.3t | CN¥770.8b | CN¥66.6b | 34.3x | 49.4x | 4.3x |
| Sun, 24 Aug 2025 | CN¥3.3t | CN¥775.3b | CN¥67.1b | 38.5x | 49.9x | 4.3x |
| Tue, 22 Jul 2025 | CN¥3.1t | CN¥780.0b | CN¥71.3b | 37x | 43.8x | 4x |
| Thu, 19 Jun 2025 | CN¥2.9t | CN¥780.0b | CN¥71.3b | 32.3x | 40x | 3.7x |
| Sat, 17 May 2025 | CN¥2.7t | CN¥786.2b | CN¥71.4b | 29.8x | 37.9x | 3.4x |
| Mon, 14 Apr 2025 | CN¥2.6t | CN¥802.7b | CN¥77.5b | 27.6x | 33.3x | 3.2x |
| Wed, 12 Mar 2025 | CN¥2.6t | CN¥800.1b | CN¥75.2b | 30.4x | 34x | 3.2x |
| Fri, 07 Feb 2025 | CN¥2.5t | CN¥800.2b | CN¥75.6b | 27.9x | 32.8x | 3.1x |
| Sun, 05 Jan 2025 | CN¥2.5t | CN¥799.8b | CN¥75.6b | 28.2x | 32.8x | 3.1x |
| Tue, 03 Dec 2024 | CN¥2.8t | CN¥799.8b | CN¥75.6b | 32.9x | 36.5x | 3.4x |
| Thu, 31 Oct 2024 | CN¥2.6t | CN¥799.5b | CN¥74.6b | 28.8x | 35.4x | 3.3x |
| Sat, 28 Sep 2024 | CN¥2.5t | CN¥798.6b | CN¥76.3b | 27.9x | 32.7x | 3.1x |
| Mon, 26 Aug 2024 | CN¥2.3t | CN¥804.2b | CN¥78.4b | 24.7x | 29.3x | 2.9x |
| Wed, 24 Jul 2024 | CN¥2.3t | CN¥804.8b | CN¥76.5b | 27.4x | 30.4x | 2.9x |
| Fri, 21 Jun 2024 | CN¥2.4t | CN¥805.5b | CN¥74.6b | 27.2x | 32.6x | 3x |
| Sun, 19 May 2024 | CN¥2.7t | CN¥821.7b | CN¥77.5b | 30.4x | 35.5x | 3.3x |
| Tue, 16 Apr 2024 | CN¥2.6t | CN¥829.0b | CN¥78.5b | 26.8x | 32.6x | 3.1x |
| Thu, 14 Mar 2024 | CN¥2.6t | CN¥832.1b | CN¥80.6b | 27.9x | 32.6x | 3.2x |
| Sat, 10 Feb 2024 | CN¥2.5t | CN¥831.3b | CN¥81.1b | 25x | 30.3x | 3x |
| Mon, 08 Jan 2024 | CN¥2.8t | CN¥830.9b | CN¥79.7b | 30.9x | 34.6x | 3.3x |
| Wed, 06 Dec 2023 | CN¥2.9t | CN¥827.9b | CN¥79.7b | 31.3x | 36x | 3.5x |
| Fri, 03 Nov 2023 | CN¥2.8t | CN¥820.4b | CN¥78.1b | 31.2x | 35.8x | 3.4x |
| Sun, 01 Oct 2023 | CN¥2.8t | CN¥824.9b | CN¥78.6b | 32.3x | 35.8x | 3.4x |
| Tue, 29 Aug 2023 | CN¥2.6t | CN¥820.4b | CN¥78.6b | 29.4x | 33x | 3.2x |
| Thu, 27 Jul 2023 | CN¥2.8t | CN¥810.8b | CN¥76.9b | 33x | 36.5x | 3.5x |
| Sat, 24 Jun 2023 | CN¥2.8t | CN¥809.7b | CN¥76.5b | 31.3x | 36.4x | 3.4x |
| Mon, 22 May 2023 | CN¥3.0t | CN¥809.1b | CN¥76.5b | 33.9x | 39.4x | 3.7x |
| Wed, 19 Apr 2023 | CN¥3.0t | CN¥801.5b | CN¥90.5b | 34.1x | 33.4x | 3.8x |
| Fri, 17 Mar 2023 | CN¥2.9t | CN¥780.1b | CN¥83.7b | 37.7x | 34.7x | 3.7x |
| Sun, 12 Feb 2023 | CN¥2.9t | CN¥774.5b | CN¥83.0b | 36.1x | 35.1x | 3.8x |
| Tue, 10 Jan 2023 | CN¥2.8t | CN¥772.3b | CN¥82.1b | 34.4x | 34.1x | 3.6x |
| Thu, 08 Dec 2022 | CN¥2.9t | CN¥767.8b | CN¥81.9b | 37.7x | 34.9x | 3.7x |
| Sat, 05 Nov 2022 | CN¥2.7t | CN¥767.3b | CN¥82.0b | 34.4x | 33.3x | 3.6x |
| Mon, 03 Oct 2022 | CN¥2.4t | CN¥760.3b | CN¥79.5b | 30.4x | 30.3x | 3.2x |
Price to Earnings Ratio
30.3x
Current Industry PE
- Investors are optimistic on the Chinese Pharmaceuticals industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 49.4x which is higher than its 3-year average PE of 35.3x.
- The 3-year average PS ratio of 3.4x is lower than the industry's current PS ratio of 4.3x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have declined 5.7% per year over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | 0.98% | |
| Healthcare | -1.55% | |
| Pharma | -1.87% | |
| Pharma | -1.87% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 002294 Shenzhen Salubris Pharmaceuticals | CN¥60.66 | 15.8% +CN¥9.2b | 88.9% | PE108.6x | |
| 300111 Zhejiang Sunflower Great Health | CN¥7.83 | 57.9% +CN¥3.7b | 222.2% | PE1403.1x | |
| 600276 Jiangsu Hengrui Medicine | CN¥70.08 | 0.6% +CN¥2.7b | 44.0% | PE63.2x | |
| 002422 Sichuan Kelun Pharmaceutical | CN¥36.90 | 1.3% +CN¥763.6m | 24.5% | PE27.5x | |
| 000661 Changchun High-Tech Industry (Group) | CN¥126.89 | 1.3% +CN¥672.9m | 27.0% | PE27.7x |